A Phase III Randomized Controlled Trial of a COVID-19 Recombinant Vaccine S-268019-B Versus ChAdOx1 nCoV-19 in Japanese Adults

In this multicenter, randomized, observer-blinded, phase III study, SARS-CoV-2–naïve participants were randomized to receive either S-268019-b or ChAdOx1 nCoV-19 as two intramuscular injections given 28 days apart.